CDK4/6 inhibition: PALOMA2 versus MONALEESA2

Share :
Published: 17 Oct 2016
Views: 3394
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Dr Gnant talks to ecancertv at ESMO 2016 about the results of the MONALEESA-2 and PALOMA-2 trials, which confirm, he says, that the addition of cell cycle inhibitors (specifically, CDK4/6) can be of great benefit to patients with metastatic breast cancer.

He discusses the results of both trials with particular regards to toxicity.

MONALEESA-2 was discussed further by Dr Gabriel Hortobagyi here, and featured in the ecancer symposium on CDK4/6 inhibitors.

Supported by a grant from Pfizer Inc.